Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice.
Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain. For this reason, the team of researchers led by Christophe Bernard at Inserm Unit 1106, “Institute of Systems Neuroscience” (INS), with the help of scientists at the École des Mines de Saint-Étienne and Linköping University (Sweden) have developed an organic electronic micropump which, when combined with an anticonvulsant drug, enables localised inhibition of epileptic seizure in brain tissue in vitro. This research is published in the journal Advanced Materials.
Drugs constitute the most widely used approach for treating brain disorders. However, many promising drugs failed during clinical testing for several reasons:
- they are diluted in potentially toxic solutions,
- they may themselves be toxic when they reach organs to which they were not initially directed,
- the blood-brain barrier, which separates the brain from the blood circulation, prevents most drugs from reaching their targets in the brain,
- drugs that succeed in penetrating the brain will act in a non-specific manner, i.e. on healthy regions of the brain, altering their functions.
Epilepsy is a typical example of a condition for which many drugs could not be commercialised because of their harmful effects, when they might have been effective for treating patients resistant to conventional treatments .
During an epileptic seizure, the nerve cells in a specific area of the brain are suddenly activated in an excessive manner. How can this phenomenon be controlled without affecting healthy brain regions? To answer this question, Christophe Bernard’s team, in collaboration with a team led by George Malliaras at the Georges Charpak-Provence Campus of the École des Mines of Saint-Étienne and Swedish scientists led by Magnus Berggren from Linköping University, have developed a biocompatible micropump that makes it possible to deliver therapeutic substances directly to the relevant areas of the brain.
The micropump (20 times thinner than a hair) is composed of a membrane known as “cation exchange,” i.e., it has negative ions attached to its surface. It thus attracts small positively charged molecules, whether these are ions or drugs. When an electrical current is applied to it, the flow of electrons generated projects the molecules of interest toward the target area.
The Latest on: Drug delivery system
via Google News
The Latest on: Drug delivery system
- Credence MedSystems Awarded Grant to Develop Its Dual Chamber Drug Delivery Device for the Global Health Settingon October 15, 2019 at 10:00 pm
The Companion ® Dual Chamber Reconstitution Syringe (C-DCS) is a user-friendly drug delivery system that maintains separation of the drug product from the diluent during storage but allows for simple ...
- Our View: Drug shortages demand close attentionon October 15, 2019 at 9:10 pm
... task force is expected to release a report on the effect of drug shortages on the nation's health care system. It should be an eye-opener for Congress and for the general public, as emerging ...
- Nanomesh drug delivery may help in fight against antibiotic resistanceon October 15, 2019 at 5:23 pm
Scientists have found a way of fabricating nanomesh so that it can be used as a drug delivery system for antibiotics, in what could be a step in the fight against global antibiotic resistance. A ...
- Electronic Drug Delivery Systems Market Worth $11.9 Billion by 2024 - Exclusive Report by MarketsandMarkets™on October 15, 2019 at 6:30 am
CHICAGO, Oct. 15, 2019 /PRNewswire/ -- According to the new market research report "Electronic Drug Delivery Systems Market By Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, ...
- U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophreniaon October 15, 2019 at 6:03 am
The once-daily transdermal drug delivery system (TDDS) provides sustained concentrations during wear time (24 hours) 2 of the atypical antipsychotic drug asenapine, a well-established treatment for ...
- Ocular Drug Delivery Technology Market : Discussion Of Market Drivers, Key Vendors And Challenges With Forecast To 2024on October 15, 2019 at 5:38 am
Different substances are used in ocular drug delivery including polymers, bioadhesive gels, and hydrogels. Furthermore, advanced drug delivery systems enable better penetration of the therapeutic ...
- Transdermal Drug Delivery System Market Growth , Leading Players and Forecast To 2023on October 14, 2019 at 5:11 am
According to Azoth Analytics research report titled "Global Transdermal Drug Delivery System Market: Analysis By Type (Patches, Gels), By Technique (Ionophoresis, Electroporation, Sonophoresis, Others ...
- The global subcutaneous drug delivery devices market is expected to reach US$ 17,290.47 Mn in 2027 from US$ 9,243.80 in 2018on October 14, 2019 at 3:51 am
Thus the growing R&D expenditure drives the subcutaneous drug delivery systems market during the forecast period. The global subcutaneous drug delivery devices market, based on the technology was ...
- Aciont Issued Key Patent Covering the Novel Design of the Visulex Ocular Drug Delivery Deviceon October 12, 2019 at 12:00 am
Aciont was issued a U.S. patent that covers an important aspect of the novel design of its main Visulex ocular drug delivery system which has been tested for safety and efficacy in its lead clinical ...
- Analysis of the Drug Delivery Devices Market, 2019-2023 - Adoption of Connected Healthcare Solutions to Improve Patient Adherence & Complianceon October 11, 2019 at 5:35 pm
Great emphasis is being placed on the targeted drug delivery system to help minimize the probability of adverse effects. This system ensures reachability with enhanced efficacy and minimal degradation ...
via Bing News